The mixture containing 250 L of 0.12 M sodium phosphate buffer, pH 8.0, 50 L of 0.5 M sodium sulfite (Sigma-Aldrich, Darmstadt, Germany), 50 L of 0.15 M D,L-dithiothreitol (DTT, Sigma-Aldrich, Darmstadt, Germany), 50 L of distilled water, 50 L of the cell homogenate, and 50 L of 0.1 M 3-mercaptopyruvate acid sodium salt (Sigma-Aldrich, Darmstadt, Germany), was incubated for 15 min at 37 C
It does not touch appetite, does not affect digestion, and does not interact with the incretin hormone system that Retatrutide engages
It reduces the risk of cardiovascular diseases
Since GLP-1RA therapy reduces energy intake primarily through appetite suppression, and observational studies suggest that dietary protein intake may also decline during treatment [75]
The main difference lies in how the medication enters the body and how consistently it is absorbed